Affyxell14 Oct 2022 09:43
Prime Medicine IPO, valuation relevant to Affyxell and potential Nasdaq listing.
Gene therapy and editing and StemCell will be a major player on the IPO scene over the next year.
Prime Medicine, a preclinical biotech developing novel gene editing therapies for various diseases, announced terms for its IPO on Thursday.
The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Prime Medicine would command a fully diluted market value of $1.7 billion.